After ‘Improprieties,’ Exicure to Wind Down XCUR-FXN Program

After ‘Improprieties,’ Exicure to Wind Down XCUR-FXN Program

315659

After ‘Improprieties,’ Exicure to Wind Down XCUR-FXN Program

Exicure is drawing to a close its XCUR-FXN program for the treatment of Friedreich’s ataxia for an unknown period of time, the company announced. The decision comes after an internal investigation concluded that data from the program’s preclinical phase would not support steps into a clinical trial, planned for this year. “Although this unfortunate event will have residual effects, I strongly believe there is great value to be unlocked at Exicure with our proprietary spherical nucleic…

You must be logged in to read/download the full post.